Matthew Capehorn

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Andrew Ahmann, Matthew Capehorn, G. Charpentier et al. · Diabetes Care · 2017 · 578 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg et al. · Diabetes & Metabolism · 2019 · 407 citations

Medicine, Pharmacology, Pharmacotherapy +16

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Ofri Mosenzon, Matthew Capehorn, Alessandra De Remigis et al. · Cardiovascular Diabetology · 2022 · 70 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Kausik K. Ray, Carlos Aguíar, Marcello Arca et al. · European Journal of Preventive Cardiology · 2024 · 70 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide

Vivian Fonseca, Matthew Capehorn, Satish K. Garg et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 62 citations · Full text

Medicine, Endocrinology, Pharmacology +17